Carbamazepine Treatment for Cocaine Dependence - 5

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
James Cornish, University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00000191
First received: September 20, 1999
Last updated: March 1, 2013
Last verified: March 2013
  Purpose

The purpose of this study is to assess carbamazepine as a pharmacotherapy for cocaine dependence.


Condition Intervention Phase
Cocaine-Related Disorders
Drug: Carbamazepine
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Carbamazepine Treatment for Cocaine Dependence

Resource links provided by NLM:


Further study details as provided by University of Pennsylvania:

Estimated Enrollment: 0
Study Start Date: January 1991
Study Completion Date: February 1994
Primary Completion Date: February 1994 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   21 Years to 51 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000191

Locations
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Sponsors and Collaborators
University of Pennsylvania
Investigators
Principal Investigator: James Cornish, M.D. University of Pennsylvania
  More Information

No publications provided

Responsible Party: James Cornish, Principal Investigator, University of Pennsylvania
ClinicalTrials.gov Identifier: NCT00000191     History of Changes
Other Study ID Numbers: NIDA-00144-5, 3R01DA012268, K20-00144-5
Study First Received: September 20, 1999
Last Updated: March 1, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Carbamazepine
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on August 26, 2014